HIV
By Morenike Oluwatoyin Folayan
Prescription of HIV pre-exposure prophylaxis (PrEP) by medical doctors in Nigeria is now possible with the registration of Truvada for use as a PrEP. ‘The registration was completed in January 2018 by Gilead representative in Nigeria,’ says Dr Chukwuma Anyaike of the Federal Ministry of Health, Abuja, Nigeria.HIV pre-exposure prophylaxis is the use of antiretroviral to prevent HIV infection in persons who are HIV negative but have substantial risk for HIV infection. The national guidelines on the use of antiretroviral in Nigeria promotes the use of tenofovir based antiretroviral drugs for use as PrEP.

The effectiveness of PrEP for the prevention of HIV infection in both men and women is globally recognized. It is able to prevent infection in persons who are HIV negative who use tenofovir-based antiretrovirals regularly and consistently. The most often prescribed tenofovir-based PrEP regimen is Truvada.

There are however gender differences in the tolerance of abuse of use of PrEP: PrEP is more forgiving in men whose risk of HIV infection is through the rectum as opposed to women whose risk of HIV infection is through the vagina. Research evidence show that for the same regimen, PrEP concentrations are lower in the vagina (compared to the rectum), meaning that high adherence to daily PrEP may be especially important for women exposed to HIV through vaginal sex.

Also, the use of PrEP by HIV negative women at substantial risk of HIV infection, during and immediately after pregnancy helps reduce the risk of HIV infection. Research evidence shows clearly that the risk of women acquiring HIV infection during the peri-conception period is significantly increased. This is a period when condom use is necessarily reduced. PrEP use during pregnancy, post-delivery and during the breastfeeding period has been strongly advocated. PrEP use during this period is safe and does not increase the risk of HIV negative  losing their pregnancy loss, having preterm birth, having babies with birth defects or congenital anomalies, or their babies having growth problems.

There is increasing concerns about why PrEP has not been rolled out in Nigeria. Nigeria has the second highest burden of HIV in the world. The concluded PrEP demonstration project conducted in Nigeria under the aegis of the National Agency for the Control of AIDS should have results to show how best to roll out PrEP in Nigeria. There are plans to share the results of the study during a satellite holding on the 14th of November 2018 at the 2018 CSO Accountability Forum.

There is also an ongoing demonstration study on the use of PrEP by men most at risk for HIV infection. The study is being implemented by the TRUST study being led by Population Council in Nigeria.

Many doctors have also been reached out to for the prescription of PrEP by persons who consider themselves at risk for HIV. The Infectious diseases Group at the University of Ibadan organized a one day session with medical doctors to provide updates on HIV management in collaboration with New HIV Vaccine and Microbicide Advocacy Society on the 1st of August 2018. Doctors present at the meeting were educated on the role as PrEP prescribers, and the care needs of persons on PrEP. In the absence of a national roadmap on how persons at substantial risk can access PrEP in Nigeria, the doctors may have to take a lead in this respect.

Dr Chukwuma Anyaike, a fearless advocate for and supporter for PrEP access in Nigeria working at the Federal Ministry of Health, feels Nigeria advocates need to be more vocal and active demanding for the roll out of PrEP. The Federal Ministry of Health has done all it should to create the supportive environment to make PrEP implementation possible. Health institutions and organization now need to take the bull by the horn and train their staff on how to facilitate PrEP access in their institutions.

For now, PrEP access is most likely going to be prescription-based. Sadly, this has large implications for access by those most vulnerable to HIV infection. The out-of-pocket expense for health in Nigeria is huge. Adolescents and young persons who are at high risk for HIV infection – those in early marriages, those with multiple sex partners, those in high HIV risk profession like sex work – are less likely to be able to access the much needed PrEP. Currently, HIV prevalence is on the increase only in the adolescent population in Nigeria.

Sadly, we can no longer wait and see. The reduced donor funding for HIV infection is starting to have its backlash – new HIV infection are being recorded in many centres in Nigeria. The government is not effectively stepping up to play its role with HIV management. There is no strategic plan to address the gaps created by donor fund withdrawal.

PrEP access is feasible in Nigeria but a lot more has to be done to make this a reality.